Synthesis, physicochemical and anticonvulsant properties of some N-substituted amides of 3-spirocycloalkylpyrrolidine-2,5-dione

Acta Poloniae Pharmaceutica - Drug Research

Volumn 60, Issue 5, 2003, Pages 383-390

  Obniska, Jolanta ^a   Zejc, Alfred ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Anticonvulsant properties; Lipophilicity; N substituted amides of 3 spirocycloalkylpyrrolidine 2,5 done; Spirosuccinimides

Indexed keywords

ACETIC ACID DERIVATIVE; AMELTOLIDE; AMIDE; ANILINE DERIVATIVE; ANTICONVULSIVE AGENT; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; CARBAMAZEPINE; CERABERSAT; HARKOSERID; IMIDAZOLE DERIVATIVE; PHENYTOIN; PROGABIDE; PYRROLIDINE DERIVATIVE; REMACEMIDE; RUFINAMIDE; SERETOLIDE; UNCLASSIFIED DRUG; VALNOCTAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CALCULATION; CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; CONVULSION; CORRELATION ANALYSIS; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; ROOM TEMPERATURE;

AMIDES; ANIMALS; ANTICONVULSANTS; CHEMISTRY, PHYSICAL; CYCLOHEXANES; CYCLOPENTANES; DRUG DESIGN; MICE; PYRROLIDINES; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0346957333     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Wong M.G., Defina J.A., Andrews P.R.: J. Med. Chem. 29, 562 (1986).
2. Jones G.P.: J. Chem. Soc. Perkin Trans. II, 415 (1987).
3. Clark C.R., Ching-Ming Lin , Sansom J.: J. Med. Chem. 29, 1534 (1986).
4. Pastalos P. Curr. Opin. in CNS Investigational Drugs 1, 5 (1999).
5. Scott K.R., Moore J.A., Zalucky T.B., Nicholson J.M., Lee J.A.M., Hinko Ch.N.: J. Med. Chem. 28, 413 (1985).
6. Edafiogho I.O., Scott K.R., Moore J.A., Farrar V.A., Nicholson J.M.: J. Med. Chem. 34, 387 (1991).
7. Serda P., Pilati T., Filippini G., Hinko C.N., El-Assadi A., Moore J., Edafiogho I.O., Andrews C.W., Cory M., Nicholson J., Scott K.R.: J. Med. Chem. 36, 3517 (1993).
8. Aleksander M.S., Stables J.P., Ciechanowicz-Rutkowska M., Hursthouse M.B., Hibbs D.E., Edafiogho I.O., Farrar V.A., Moore J. A., Scott K.R.: Eur. J. Med. Chem. 31, 787 (1996).
9. Lien E.: J. Med. Chem. 13, 1189 (1970).
10. PALLAS (version for Windows 1.2) Log P Prediction Module: Prolog P 5.1, Compu. Drug Chemistry Ltd. (1995).
11. Zejc A., Obniska J., Wilimowski M., Rutkowska M., Witkowska M., Barczyńska M., Kedzierska Goziak L., Wojewódzki W., J., Orzechowska-Juzwenko K., Pławiak T., Duś E., Gryska J., Gliniak H.: Pol. J. Pharmacol. Pharm. 42, 69 (1990).
12. Obniska J., Kulig K., Zejc A.: Acta Polon. Pharm. - Drug Res. 55 (3), 223 (1998).
13. Obniska J., Zejc A., Karolak-Wojciechowska J.: Il Farmaco 54, 423 (1999).
14. Obniska J., Zejc A., Zagórska A.: Acta Polon. Pharm. - Drug Res. 3, 56 (2002).
15. El-Telbany F.A., Ghoneim K.M., Khalifa M.: Pharmazie 31, H. 7, 442 (1976).
16. El-Telbany F.A., Ghoneim K.M., Khalifa M.: Pharmazie 32, H. 1, 22 (1977).
17. Bodanszky M., Bodanszky A.: in The Practice of Peptide Synthesis, Eds. Springer-Verlag Berlin Heidelberg New York Tokyo 149, 1984.
18. Swinyard E.A.: Anticonvulsant Drugs, Section 19 vol. 1, Pergamon Press, Oxford and New York 47, 1972.
19. Kupferberg H.J.: Epilepsia 30, 551 (1989).